Menu
With over 40 years of experience in the industry, including prominent roles as CEO of Siemens Healthineers and CEO of Siemens Healthcare Diagnostics, Tomas Kramar has an impressive career in life science. His decision to join SpectraCure’s board reflects his belief that the company has the potential to offer an exciting and promising solution for prostate cancer treatment in the future.
Do you want to learn more about Tomas Kramar and hear what he considers unique about SpectraCure? Don’t miss the interview!
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.